Literature DB >> 19589912

Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma.

Victoria White1, Cinzia Scarpini, Nuno L Barbosa-Morais, Emili Ikelle, Stephanie Carter, Ronald A Laskey, Richard Miller, Nicholas Coleman.   

Abstract

BACKGROUND: Promising stool-based screening tests for colorectal carcinoma (CRC) rely on detection of exfoliated colonocytes or their contents. However, methods of colonocyte retrieval have not been studied systematically and current approaches are restricted by low yields. We examined colonocyte numbers in stool wash fractions and assessed the suitability of retrieved cells for immunocytochemistry for minichromosome maintenance protein 2 (MCM2), a marker of the proliferative deregulation that characterizes malignancy.
METHODS: Colonocyte numbers were accurately quantified in 129 wash fractions derived from 18 stools, comparing the mucus retained by a 125-microm filter (F fraction) with the fine and coarse content in the filtrate (S and P fractions, respectively). MCM2 immunocytochemistry was done on sections of fibrin clot containing filter-derived mucus, obtained from stools of eight independent subjects.
RESULTS: Total colonocyte yield in the F fraction (mean, 433.8 per 100 microL) was higher than in the S (140.3) and P (204.6) fractions (P = 0.004 and 0.03, respectively) due to increased numbers of morphologically abnormal cells, which predominantly represented malignant cells in samples from CRC patients. Several thousand abnormal cells could be obtained from stool-derived mucus in all CRC patients, an order of magnitude greater than numbers in subjects without CRC. Median MCM2 labeling index in abnormal cells was 50% (range, 30-60%) in CRC patients and 0% in subjects without CRC. Cells in clot sections were well preserved and not obscured by fecal debris.
CONCLUSIONS: Isolation of stool-derived mucus is technically straightforward and can improve the performance of protein-based and/or nucleic acid-based approaches to CRC screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589912     DOI: 10.1158/1055-9965.EPI-08-1145

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

Review 1.  Replication proteins and human disease.

Authors:  Andrew P Jackson; Ronald A Laskey; Nicholas Coleman
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-01-01       Impact factor: 10.005

Review 2.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

Review 3.  Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

Authors:  Giulia De Maio; Claudia Rengucci; Wainer Zoli; Daniele Calistri
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

4.  Nano-architectural alterations in mucus layer fecal colonocytes in field carcinogenesis: potential for screening.

Authors:  Hemant K Roy; Dhwanil P Damania; Mart DelaCruz; Dhananjay P Kunte; Hariharan Subramanian; Susan E Crawford; Ashish K Tiwari; Ramesh K Wali; Vadim Backman
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-27

Review 5.  Colon mucus in colorectal neoplasia and beyond.

Authors:  Alexandre Loktionov
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

6.  Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening.

Authors:  Dhananjay P Kunte; Mart DelaCruz; Ramesh K Wali; Ashwaty Menon; Hongyan Du; Yolanda Stypula; Amir Patel; Vadim Backman; Hemant K Roy
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.